Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1604-1609, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudenski, A. S.
Right arrow Articles by Halsall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rudenski, A. S.
Right arrow Articles by Halsall, D. J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:1604-1609.)
© 1998 American Association for Clinical Chemistry, Inc.

Test Utilization and Outcomes

Genetic testing for Gilbert's syndrome: how useful is it in determining the cause of jaundice?

Aram S. Rudenskia, and David J. Halsall

Department of Clinical Biochemistry, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QR, UK.
a Author for correspondence. Fax 44-1223-217862; e-mail ar223{at}cam.ac.uk.

Gilbert's syndrome is a benign condition causing hyperbilirubinemia, which is also a symptom of liver or hemolytic disease. A genetic test may be possible for Gilbert's syndrome because an associated gene defect has been isolated. Here we present a mathematical analysis of the use of this test in excluding harmful causes of hyperbilirubinemia. The effectiveness of the test depends on a low prevalence and high penetrance of the gene defect and a low prevalence of harmful hyperbilirubinemia. If the gene defect has a 12% prevalence and 10% penetrance, then the prevalence of harmful hyperbilirubinemia needs to be <1.5% for a positive test to reduce this risk fivefold. Estimates of the prevalence of harmful hyperbilirubinemia and of the prevalence and penetrance of the Gilbert genotype are required to assess the value of the genetic test in determining a cause of hyperbilirubinemia. Until these values for prevalence and penetrance are known, genetic testing for Gilbert's syndrome cannot be recommended on a routine basis.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. R. Harraway and P. M. George
Use of Fully Denaturing HPLC for UGT1A1 Genotyping in Gilbert Syndrome
Clin. Chem., November 1, 2005; 51(11): 2183 - 2185.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. L. Biondi, O. Turri, D. Dilillo, G. Stival, and E. Guagnellini
Contribution of the TATA-Box Genotype (Gilbert Syndrome) to Serum Bilirubin Concentrations in the Italian Population
Clin. Chem., June 1, 1999; 45(6): 897 - 898.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.